Journal of Basic & Clinical Medical Sciences2959-92022959-92102022-09-13515410.58398/0002.000037articleAtif AdnanInstitute of Life Sciences, Shenyang Medical College, Shenyang, P.R. ChinaLiaoning Province Key Laboratory for Phenomics of Human Ethnic Specificity and Critical Illness, Shenyang Medical College, Shenyang, P.R. ChinaLiaoning Provincial Belt and Road Joint Laboratory for China-Pakistan Human Phenomics Research, Shenyang Medical College, Shenyang, P.R. ChinaThe use of machine learning has changed how molecular and clinical data are used to detect disease, forecast prognosis and select treatment, yet a gap remains between reported performance and clinical use. Few published models have been tested prospectively, and several that have reached practice perform far worse than expected. From this perspective, I argue that clinical translation should be seen as a continuum from data to decision. Three weaknesses explain much of the gap: models whose outputs cannot be checked against biology, data that are unrepresentative or inconsistently recorded, and the absence of shared standards for evaluation and oversight. I propose a five-stage framework that links representative, high-quality data; clinically interpretable models; external and prospective validation; workflow integration; and postdeployment monitoring and governance. Low- and middle-income countries need locally governed data and regional validation networks rather than imported tools. The goal is safer, more equitable clinical decisions, not better prediction alone.